Overview

• The manufacturer of the abortion pill mifepristone has asked the Supreme Court to review restrictions imposed by a lower court ruling.
• The restrictions include barring telemedicine prescriptions and mail delivery of mifepristone.
• The Biden administration has also appealed to defend the existing federal approval of mifepristone, deemed safe and effective by medical organizations.
• The Supreme Court's decision, expected by early summer 2024, will determine nationwide access to medication abortion.
• This is the most high-profile abortion case since Roe v. Wade was overturned, carrying implications for reproductive rights.